Earlier this week, Switzerland-based eye care company Alcon Inc. (ALC) announced its entry into a definitive agreement to acquire Aerie Pharmaceuticals, Inc. (AERI) for $770 million.
Through this acquisition, ALC will add commercial products like Rocklatan and Rhopressa. It will also add AR-15512, a phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates.
